SLC2A4RG (SLC2A4 regulator) is a transcription factor that functions as a tumor suppressor through its ability to transactivate apoptotic genes. The protein demonstrates cytoplasmic/nuclear shuttling capability and directly transactivates caspase-3 and caspase-6 genes to induce apoptosis and attenuate cell proliferation via G2/M phase arrest 1. Its tumor suppressor function depends on nuclear localization, but this activity is negatively regulated by 14-3-3θ protein, which sequesters SLC2A4RG in the cytoplasm and reverses its pro-apoptotic effects 1. The gene has been identified in the 20q13.33 chr20 region associated with glioma susceptibility through genome-wide association studies 1. SLC2A4RG contains iron response elements that can bind iron-regulatory proteins, as detected through structural footprinting analyses 2. Additionally, variants in SLC2A4RG have been identified as potential microRNA-binding site targets in multiple sclerosis susceptibility studies, suggesting broader roles in autoimmune diseases 3. However, polymorphisms in SLC2A4RG do not appear to be associated with polycystic ovary syndrome phenotypes 4. The protein's dual localization and regulation by 14-3-3θ represents a novel oncogenic mechanism with potential therapeutic implications for glioma treatment.